Trial Profile
A study evaluating efficacy of Rivaroxaban for post thrombotic syndrome in patients with venous thromboembolism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2018
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 27 Feb 2018 New trial record
- 12 Feb 2018 Results published in the American Journal of Medicine